Abstract: The inventive concept provides a substrate treating apparatus. The substrate treating apparatus includes a chamber having a treating space therein; a supply line having a first open/close valve installed thereon and configured to supply a treating fluid to the treating space; a heater installed on the supply line and configured to heat the treating fluid; an exhaust line having a second open/close valve installed thereon and configured to exhaust the treating space; and, a controller configured to control the first open/close value and the second open/close valve such that the treating fluid heated is supplied to and exhausted from the treating space before a treating process is performed on a substrate in the treating space.

Abstract: A new use of hydroxyurea for preventing, alleviating, or treating systemic inflammatory response syndrome or sepsis is disclosed. Hydroxyurea can control the activity of neutrophils that are immune cells involved in inflammatory mechanisms, and thus can protect an individual from side effects or conditions caused by systemic inflammatory responses which can occur due to exposure to microorganisms such as bacteria or viruses. Thus, a pharmaceutical composition containing hydroxyurea as an active ingredient can prevent, alleviate, or treat systemic inflammatory response syndrome or sepsis in an individual and ultimately can remarkably increase the survival rate of the individual. The composition may be effective in preventing, alleviating, or treating neutrophilia which can occur when exposed to microorganisms such as bacteria or viruses, wherein the viruses include viruses for therapeutic purposes, such as oncolytic viruses as well as pathogenic viruses such as influenza virus or coronavirus.